RespiDerm Corporation’s AirJector® noninvasive transdermal medical gas delivery device has satisfied all European Conformity requirements for a low-risk medical device!
Little Rock, AR—July 10, 2017—AirJector® has received the right to carry the CE mark, signifying that the AirJector® system and therapeutic treatment is safe, low risk, and effective for its indications. The CE mark is enabling the commercialization of the AirJector® in all European countries, as well in other countries where the European medical device approval is recognized. CE is an acronym for the French translation of “European Conformity,” and is an indicator of a product’s compliance with the European Union legislation regarding protection. AirJector® is the first noninvasive transdermal gas delivery system receiving certificate in the European Union to safely deliver medical gases into the microcapillaries for its indications. “Because of the CE marking, treatment providers and patients can be assured that the AirJector® meets all EU safety, usability, health, and environmental requirements,” said Mr. Tibor Salamon, CEO of Respiderm.